GCM
ZVRA icon

Graham Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Graham Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$169K Buy
+11,764
New +$131K ﹤0.01% 1073
2025
Q4 		– Sell
-41,452
Closed -$394K – 1627
2025
Q3 		$394K Buy
+41,452
New +$416K 0.01% 718

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Graham Capital Management's ZVRA Position: Q2 2026 in Review

Graham Capital Management opened a new position in Zevra Therapeutics (ZVRA) in Q2 2026: 11,764 shares worth $169K. The stake represents ﹤0.01% of the portfolio and ranks #1073 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in ZVRA as recently as Q3 2025.

Graham Capital Management first reported a position in ZVRA in Q3 2025 and has held it in 2 quarters since. The position peaked at $394K in Q3 2025. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Graham Capital Management held 11,764 shares of Zevra Therapeutics worth $169K as of Q2 2026.
  • Zevra Therapeutics was a new Graham Capital Management position in Q2 2026.
  • Zevra Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1073 holding.
  • Graham Capital Management first reported a position in Zevra Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Graham Capital Management's Zevra Therapeutics position peaked at $394K in Q3 2025.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.